Clinical Trial Update: Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating corifollitropin alfa followed by hpHMG in a short GnRH agonist protocol for poor ovarian responders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infertility
• Poor Ovarian Response

Drugs mentioned

• Corifollitropin alfa (Corifollitropin alfa)
• hpHMG (hpHMG)

Snippet

Sponsor: Universitair Ziekenhuis Brussel | Conditions: Infertility, Poor Ovarian Response | Phase 2 | Status: COMPLETED